What's new? Log in Free sign up

Table search / Registration and prospectus / Ensysce Biosciences, Inc.

245 results

Newest first

ENSC Ensysce Biosciences, Inc.

IPO registration (amended)

SCHEDULE OF DEBT

		Principal balance				Accrued interest				Unamortized Debt Discount & Issuance Costs				Net debt balance
2023 Notes		$	1,836,000			$	13,078			$	(1,197,200)			$	651,878
Financed insurance			197,249				5,570				-				202,819
Total		$	2,033,249			$	18,648			$	(1,197,200)			$	854,697

26 Mar 24

4:44pm

ENSC Ensysce Biosciences, Inc.

IPO registration (amended)

SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS

		December 31, 2023				December 31, 2022
Exercise price			$1.13 - 1.18				$103.20 - 1,507.20
Expected stock price volatility			106.77% - 106.82	%			76.61% - 95.87	%
Expected term (years)			5.00				5.19-10.00
Risk-free interest rate			4.62% - 4.89	%			1.52% - 3.14	%
Expected dividend yield			0	%			0	%

26 Mar 24

4:44pm

ENSC Ensysce Biosciences, Inc.

IPO registration (amended)

SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION

		2023				2022
		Year ending December 31,
		2023				2022
Income (benefit) taxes at statutory rates			(2,231,518)				(5,083,614)
State income tax, net of federal benefit			(77,243)				(175,164)
Warrants and convertible debt			(90,392)				(234,214)
Nondeductible executive compensation			2,107				-
Stock based compensation			580,823				303,499
Share subscription facility transaction costs			-				20,335
Research and development tax credits			(629,239)				(1,028,988)
Change in tax rates			(3,848)				54,263
Other			77,162				(78,227)
Change in valuation allowance			2,372,148				6,222,110
Total			-				-

26 Mar 24

4:44pm

ENSC Ensysce Biosciences, Inc.

IPO registration (amended)

		Total				Level 1				Level 2				Level 3
		December 31, 2022
		Total				Level 1				Level 2				Level 3
Fair value of convertible note		$	4,203,579			$	-			$	-			$	4,203,579
Liability classified warrants			310,346				-				-				310,346
Total		$	4,513,925			$	-			$	-			$	4,513,925

26 Mar 24

4:44pm

ENSC Ensysce Biosciences, Inc.

IPO registration (amended)

SCHEDULE OF DEFERRED TAX ASSETS

		2023				2022
		As of December 31,
		2023				2022
Deferred tax assets:
Net operating loss tax carryforwards		$	28,485,164			$	26,726,066
Tax credits			4,793,138				4,164,187
Capitalized research costs			4,368,767				3,729,483
Stock-based compensation			746,444				1,173,158
Other			31,279				265,677
Gross deferred tax assets			38,424,792				36,058,571
Valuation allowance			(38,424,792)				(36,052,644)
Total deferred tax assets			-				5,927
Deferred tax liabilities:
Other			-				(5,927)
Total deferred tax liabilities			-				(5,927)
Net deferred tax assets		$	-			$	-

26 Mar 24

4:44pm

mbculhj3uke epwbldst

IPO registration (amended)

26 Mar 24

4:44pm

wnb9vx394ae2jos8r

IPO registration (amended)

26 Mar 24

4:44pm

qx0w6rhjykaqh3w6

IPO registration (amended)

26 Mar 24

4:44pm

IPO registration (amended)

26 Mar 24

4:44pm

nqnbrm kcxbb2vpsonr0

IPO registration (amended)

26 Mar 24

4:44pm

IPO registration (amended)

26 Mar 24

4:44pm

85v8d3wxod ycva

IPO registration (amended)

26 Mar 24

4:44pm

IPO registration (amended)

26 Mar 24

4:44pm

i9rt8 pg3mzg7tv

IPO registration (amended)

26 Mar 24

4:44pm

IPO registration (amended)

26 Mar 24

4:44pm

fy6c06owkmx3x3jyxrpp

IPO registration (amended)

26 Mar 24

4:44pm

IPO registration (amended)

26 Mar 24

4:44pm

5lbfwirz j60xbg

IPO registration (amended)

26 Mar 24

4:44pm

xkx uf0dhjbhour

IPO registration (amended)

26 Mar 24

4:44pm

IPO registration (amended)

26 Mar 24

4:44pm

Prev
1
2
3
4
5
...
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.